WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (NASDAQ: NURO) announced today that it has entered into a definitive securities purchase agreement with a healthcare dedicated institutional investor in connection with a private placement of 7,000 shares of Series F convertible preferred stock

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq: NURO) today reported that Michael MacDonald has been promoted to SVP and General Manager of Diagnostics. In this role, Mr. MacDonald will oversee the Company's diagnostic products which include DPNCheck ® and ADVANCE™. Mr.

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq: NURO) today provided an update on its data science initiative and the related Quell ® Health Cloud. Data science consists of the development of large cloud databases and the use of powerful analytical tools such as machine learning and

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq: NURO) today provided an update on its Quell ® clinical program. Quell is a wearable non-invasive neurostimulator that provides widespread analgesia for chronic pain. In addition to delivery of therapy, the device and its associated

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,675,801. The patent covers novel mechanisms to help Quell ® users safely obtain pain relief therapy over prolonged time periods.

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (NASDAQ:NURO) today announced that Shai N. Gozani M.D., Ph.D., President and CEO of NeuroMetrix , is scheduled to speak at the upcoming 2017 Marcum Microcap Conference at the Grand Hyatt Hotel in New York City. Dr.

Waltham -based company to exhibit its wearable device for widespread chronic pain relief BOSTON --(BUSINESS WIRE)-- NeuroMetrix, Inc.  (Nasdaq: NURO) is showing  Quell ® , its 100% drug-free Wearable Pain Relief Technology™ to sleep medicine professionals from around the world at SLEEP 2017 , the

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (NASDAQ:NURO) today announced that Shai N. Gozani M.D., Ph.D., President and CEO of NeuroMetrix , is scheduled to speak at the upcoming LD Micro Invitational at the Luxe Sunset Bel Air Hotel in Los Angeles, CA. Dr.

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,656,070. The patent covers the novel application of real-time accelerometer measurements to control transcutaneous electrical nerve stimulation.

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq:NURO) announced that it was the recipient of the Smaller Businesses Association of New England (SBANE) New England Innovation Award for the development and successful launch of Quell ® Wearable Pain Relief Technology™.